Diagnostic value of lipids, total antioxidants, and trace metals in benign prostate hyperplasia and prostate cancer by Adedapo, KS et al.
293Nigerian Journal of Clinical Practice • Jul-Sep 2012 • Vol 15 • Issue 3
Original Article
Abstract
Background: Considerable overlap exists in the value of total prostate specific antigen (tPSA) in both prostate cancer 
(Pca) and benign prostate hyperplasia (BPH). Developing an effective biochemical screening test that will complement 
PSA assay could reduce the associated cost of care and give timely attention to prostate cancer patients even when they 
are still asymptomatic is therefore desirable. This work was therefore an attempt to evaluate the possible roles of lipids, 
antioxidants, and trace metals in breaking the diagnostic tie between Pca and BPH.
Materials and Methods: Anthropometric characteristics, total prostate specific antigen (tPSA), serum lipids (total cholesterol, 
LDL cholesterol, HDL cholesterol, and triglycerides), Vit. E, total antioxidant status (TAS), and trace metals (Se, Cu, Fe, 
Zn, and Mn) were determined in 40 patients with histopathological diagnosis of BPH and Pca. Forty age matched control 
subjects were also recruited from the same community. Informed consent was obtained from all the participants in the study. 
A P-value < 0.05 was considered significant.
Results: There were significant variations in the weight, hip circumference, and body mass index (BMI) across the group 
but the post hoc test did not show any difference between patients with prostate cancer and BPH. Among the biochemical 
parameters studied, only the total cholesterol and triglyceride differed significantly between patients with BPH and prostate 
cancer patients. Cut-offs from ROC for BPH and prostate cancer at 88.9 sensitivity and 66.7% specificity (95% CI) were 
88.5 mg and 161 mg/dl for triglycerides and cholesterol  respectively. Furthermore there were no significant variations in 
the mean levels of copper and tPSA, Vit E, and LDL cholesterol among the study subjects and the controls.
Conclusion: Prior to prostate biopsy, serum lipid (especially, fasting triglycerides, total cholesterol) could help in early 
discrimination of patients with BPH from prostate cancer in adjunct to total PSA and other management protocol for diagnosis 
of prostate cancer. The use of trace metal or antioxidants may have limited advantages. Further studies in this regard will 
be very desirable to see if this pattern of triglyceride and total cholesterol values in BPH and Pca are sustainable.
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Introduction
Prostate cancer (Pca) and benign prostate hyperplasia 
(BPH) are diseases of the male above the age of 50 years 
worldwide.[1] While BPH is a benign enlargement of the 
prostate gland requiring medical or surgical intervention to 
relieve obstruction to urinary flow, prostate cancer is a life-
threatening malignancy with grave morbidity and mortality 
because of its tumor burden and metastatic potentials. The 
management of benign prostate hyperplasia differs from that 
of prostate cancer given the different outcomes of their 
natural history. It is therefore important to have tools that 
are sensitive and specific enough to make an appropriate 
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early diagnosis so as to institute appropriate treatment. This 
would in turn improve the quality of life of affected persons. 
There is however a limitation in diagnosis of these diseases 
due to the considerable overlap in the value of total PSA 
in both conditions especially in the African population.[2]
Several investigators outside Nigeria have used various 
diagnostic profiles to discriminate between BPH and Pca. Some 
workers have compared the ratio of free to total PSA or free to 
complexed PSA.[3,4] Others have used plasma lipid levels,[5,6] 
vitamin E (α and γ tocopherol),[7] trace metal-Selenium,[8] and 
serum to urinary PSA ratio.[9,10] These previous studies have 
produced varying outcomes with merits and shortcomings. 
Most clinicians and urologists in Nigeria however use total PSA 
largely in the initial biochemical investigation of the patients 
presenting with symptoms referable to the prostate gland. This 
work was therefore an attempt to evaluate the possible roles of 
lipids, antioxidants, and trace metals in breaking the diagnostic 
tie between Pca and BPH.
The human body is constantly exposed to the attack of free 
radicals. Reactive oxygen species (ROS) collectively described 
as free radicals such as superoxide (O2-), hydroxyl (OH-), 
and other nonradical oxygen derivatives such as hydrogen 
peroxide (H2O2) play a significant role in the pathogenesis 
of many diseases such as atherosclerosis, diabetes mellitus, 
cancer, cardiovascular disease, liver disease, lung disease, 
neurodegenerative disease, inflammatory, and infectious 
diseases.[11] Free radicals are highly reactive molecules 
generated by the biochemical redox reactions that occur as 
part of normal cellular metabolism. Lipid peroxidation caused 
by free radicals could be prevented by antioxidants defense 
mechanisms both intracellularly and extracellularly. These 
include the antioxidant enzymes glutathione, superoxide 
dismutase (SOD), catalase (CAT), glutathione peroxidase 
(GSH-Px), glutathione S-transferase (GST), and glutathione 
reductase (GR).[12] Srivastava and Mittal[13] demonstrated 
increased level of serum lipid peroxide in patients with 
both benign prostate hyperplasia and cancer. Among the 
micronutrients the protective role of the various antioxidant 
vitamins (C, alpha and beta carotene) in fruits and vegetables 
is of great importance in diet. Fruit consumption has been 
shown in numerous studies to offer strong protection against 
certain cancers, especially oral, and pharyngeal, lung, prostate, 
and pancreatic cancer. [14] Epidemiological studies indicate 
that selenium and zinc may also serve as chemopreventive 
agents that suppress the growth and dissemination of prostate 
cancer. [15] Kamat and Lamm[16] however deduced from their 
work that reduced fat intake, vit E, selenium, and soy protein 
are associated with prevention of prostate cancer. In Nigeria, 
an earlier study[17] suggested the use of selenium supplement 
among others in the management of prostate cancer.
This study was therefore designed to evaluate the diagnostic 
role of lipids, trace metals, and antioxidants in patients with 
BPH and Pca.
Materials and Methods
Total PSA, plasma lipids (total cholesterol, LDL 
cholesterol, HDL cholesterol, and triglycerides), Vit. E, 
total antioxidant status (TAS), and trace metals (Se, Cu, 
Fe, Zn, and Mn) were determined in two groups of 40 
patients with histopathological diagnosis of BPH and Pca 
respectively and 40 age-matched control subjects selected 
within the same community who gave their consent. The 
patients were recruited from the urology clinic of the 
University College Hospital for symptoms referable to 
prostate disease. Informed consent was obtained from all 
the patients that participated in the study. Fasting blood 
sample was collected for lipid analysis. Plasma separated 
from these samples was refrigerated at -20°C until batch 
analysis within 2 weeks.
Plasma total antioxidant status was determined by the 
method of Koracevic et al.[18] A standard solution of 
Fe-EDTA complex reacts with hydrogen peroxide by a 
Fenton- type reaction, leading to the formation of hydroxyl 
radicals. These reactive oxygen species degrade benzoate, 
resulting in the release of thiobarbituric acid reactive 
substance. The rate of inhibition of color is proportional to 
the concentration of antioxidative activity.
Trace metal concentration was determined by an atomic 
absorption spectrophotometer (AAS) using a direct method 
previously described by Kaneko.[19] The method is based on 
the principle that atoms of the element aspirated into AAS 
absorb light of the same wavelength as that emitted by the 
element when in the excited state.
Vitamin E was determined by the method of Baker[20] which 
is based on the principle that vitamin E extracted in xylene 
react with alpha dipyridyl with the production of a red color 
with ferric chloride read by spectrophotometer at 520 nm.
Lipid fractions were analyzed by methods previously 
described.[21]
Statistical analysis was done using the SPSS Software 
version 15.0. The data were expressed as mean ± standard 
deviation for patients and control separately. Anova 
(F-value) was used to compare the difference between 
the means of the three groups studied, while the post hoc 
Student’s t test was used to compare the difference between 
the means of the study subjects; a P value < 0.05 was 
considered significant.
Results
Table 1 shows the anthropometric characteristics between 
the study subjects patients and controls. There were 
significant variations in the weight, hip circumference, 
and BMI across the group but the post hoc test did not 
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show any difference between patients with prostate 
cancer and BPH. Among the biochemical parameters 
studied, only the total cholesterol and triglyceride levels 
differed significantly between patients with BPH and 
prostate cancer patients (155.1 ± 49.8 vs. 188.7 ± 31.7 
mg/dl P<01 , 87.9 ± 27.7 vs. 136.7 ± 59.1 mg/dl; P = 
0.0004 respectively). Receiver operative characteristics 
with sensitivity and specificity fixed at 88.9 and 66.7% 
respectively gave cut-off values of 88.5 and 161 mg/
dl respectively for triglyceride and total cholesterol as 
discriminatory between patients with BPH and prostate 
cancer [Table 2].
Furthermore there were no significant variations in the 
mean levels of copper and tPSA, Vit E, and LDL cholesterol 
among the study subjects and the controls [Table 3]. 
The level of tPSA however did not show any significant 
correlation with Vit E, LDL cholesterol, and triglyceride 
respectively among the groups.
Discussion
The need to increase the diagnostic sensitivity of 
biochemical tests to enhance discrimination between 
prostate cancer and BPH has been a topical issue for quite 
some time. In a resource scarce environment as obtained 
in many developing countries in Africa, developing an 
effective biochemical screening tests that will complement 
PSA assay will therefore reduce the associated cost of care 
and give timely attention to prostate cancer patients even 
when they are still asymptomatic.
While the different panels associated with PSA either total, 
free or complexed PSA or the free to complexed ratio are 
still nonspecific, the use of total PSA velocity has been 
found useful. Understanding the pathogenesis of prostate 
cancer development may therefore throw some light on what 
early derangement may point to presence of cancer. To this 
end several workers have looked at various micronutrients, 
antioxidant vitamins, and trace metals.
The mean circulating triglyceride was found to be 
significantly different in this study between the study 
patients and controls. It was also significantly higher 
(1.6 times) in patients with prostate cancer compared to 
BPH patients. This observation agrees with the finding 
of Wuermli et al.[6] who observed a positive correlation 
between serum triglyceride (Tg) and prostate cancer. 
Furthermore, it was observed that hypertriglyceridaemia 
may increase the risk of prostate cancer and can thus be 
used for prognostication. A similar significant difference 
was observed for total cholesterol in this study between 
patients with BPH and Pca. It was reported by Freeman 
and Solomon[22] in a review that a number of studies 
had demonstrated that cholesterol accumulates in solid 
tumors and that cholesterol homeostasis breaks down 
in the prostate with aging and with transition to the 
malignant state. This could probably account for the level 
of circulating total cholesterol in this study being lower than 
200 mg/dl. Thus among the lipid panel, total cholesterol 
and triglyceride are a promising tie-breaker between these 
two disease entities. Receiver operative characteristics 
(ROC) transformation on the present data supports serum 
triglycerides greater than 88.5 mg/dl and total cholesterol 
of 161 mg/dl as increased risk for development of prostate 
cancer.
Dietary fat is a well-established risk factor in cardiovascular 
disease. Hypertriglyceridemia and elevated waist 
circumference have been identified by Kahn and Valdez[23] 
as a phenotype for higher risk for cardiovascular disease. 
Others have found increased plasma triglyceride to be 
associated with the metabolic syndrome.[24] However, obesity 
as evidenced by the normal BMI in the patients with prostate 
cancer is not a feature of the patients studied. These findings 
suggest the interplay of several other factors apart from lipid 
Table 1: Anthropometric measurement in study 








Age (years) 65.2 (6.72) 68.5 (9.6) 64.5 (10.3) 0.110
Height (m) 1.7 (0.08) 1.70 (0.1) 1.70 (0.1) 1.002
Weight (kg) 69.6 (14.0) 60.5 (14.9) 69.2 (11.5) 0.004*
Hip circumference (cm) 99.4 (1.9) 91.9 (7.8) 97.7 (6.3) 0.001*
Waist circumference (cm) 87.4 (11.3) 86.2 (6.6) 90.1 (8.7)  0.148
BMI (kg/m2) 23.9 (4.6) 21.03 (3.9) 24.0 (4.6) 0.004*
Systolic BP (mmHg) 137.7 (29.0) 132.5 (21.5) 138.6 (22.4)  0.488
Diastolic BP (mmHg) 91.1 (129) 86.0 (9.9) 92.3 (14.7)  0.065
Table 3: Biochemical parameters in study subjects and 








Total PSA (mg/L) 3.2 (2.47) 92.7 (60.5) 55.1 (59.7) 0.002*
Se (mg/dl) 59.7 (12.3) 58.6 (12.8) 57.6 (11.2) 0.741
Cu (mg/dl) 45.9 (6.2) 43.6 (9.5) 41.2 (9.4) 0.051*
Fe mg/dl 61.7 (12.3) 60.6 (12.8) 59.8 (11.3) 0.782
Zn (mg/ml) 114.4 (25.2) 119.8 (25.2) 126.0 (22.4) 0.107
Mn (mg/ml) 36.8 (5.8) 37.1 (7.9) 34.5 (6.4) 0.175
Vit E (mg/dl) 15.2 (1.6) 10.9 (1.0) 10.9 (2.6) 0.001*
TAS (mmol/l) 1.2 (0.43) 1.0 (0.5) 1.0 (0.4) 0.072
T/Cholesterol (mg/dl) 157.1 (27.5) 188.7 (31.7) 155.1 (49.8) 0.001 *†
LDL/cholesterol (mg/dl) 84.9 (4.6) 116.9 (26.9) 108.0 (37.4) 0.003*
HDL/cholesterol (mg/dl) 48.6 (19.3) 44.3 (10.5) 49.9 (14.7) 0.233
Triglycerides (mg/dl) 114 (63.1) 136.7 (59.1) 87.9 (27.7) 0.001*,†
*Anova. †Post hoc significant difference between Pca and BPH.
Table 2: Receiver operative characteristic for Tg and 
T/cholesterol in study subjects
Parameter Cut-off Sensitivity % Specificity %
Tg 88.5 mg/dl 88.9 66.7
T/cholesterol 161 mg/dl 88.9 66.7
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in the pathogenesis of prostate cancer. In another study by 
Van Hemelrijck et al.[25] there was a positive association 
between hypertriglyceridaemia and prostate cancer risk 
when there was a high glucose level. This has introduced 
another variable not considered in our study.
The level of trace metals and total antioxidant status were not 
found to be diagnostic in this study. It could be opined that 
the level of intake of antioxidants in the study and subject 
population was significant enough to provide the protection 
from oxidative stresses especially lipid peroxidation. Unlike 
the findings in this study Ayidin et al.[26] established that 
an altered prooxidant--antioxidant status may lead to an 
increase in oxidative damage and play a possible role in 
prostate carcinogenesis. Consumption of animal fats has been 
associated with increased prostate cancer risk.[27] A study by 
Key et al.[28] on plasma carotenoids, retinol, and tocopherols 
on the risk of prostate cancer in Caucasians found none 
of the micronutrients to be significantly associated with 
prostate cancer risk. However, a more recent prospective 
study by Mondul et al. observed that men with higher serum 
retinol level at base line were more likely to develop prostate 
cancer.[29] While dietary factor was not directly studied in 
this work, yet an indirect relationship could be inferred 
from the submission of Chan et al.,[30] who together with his 
colleagues identified the role of Insulin-like growth factor-
1(IGF-1) in prostate carcinogenesis. This hormone normally 
efficiently manages the rate of cell growth and remodeling. In 
unhealthy conditions IGF-1 becomes more active increasing 
the formation of new cells and simultaneously inhibiting 
the removal of old cells - which favors the development of 
cancer.[30] Consumption of animal-based foods and dairy 
increases the blood level of this growth hormone. The study 
further noted that in prostate cancer people with higher than 
normal IGF-1 have five fold increased risk of advanced stage 
prostate cancer. This report has also been corroborated in a 
multicenter prospective meta-analysis[31] that the greater the 
serum IGF-1 concentration the greater the subsequent risk 
for prostate cancer.
Conclusion
Before prostate biopsy is carried out, serum lipid (fasting 
triglycerides >88.5 mg/dl, total cholesterol >161 mg/dl) 
could help in further discrimination of patients with BPH 
from prostate cancer patients in adjunct to total PSA for 
diagnosis of prostate cancer. The use of trace metal or 
antioxidants has limited advantages. Further studies in 
this regard will be very desirable to see if this pattern of 
triglyceride and total cholesterol values in benign prostatic 
hyperplasia and prostate cancer are sustainable.
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